Alliancebernstein L.P. Increases Stake in Audentes Therapeutics Inc (BOLD)

Alliancebernstein L.P. lifted its holdings in Audentes Therapeutics Inc (NASDAQ:BOLD) by 40.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 660,281 shares of the biotechnology company’s stock after purchasing an additional 189,825 shares during the quarter. Alliancebernstein L.P. owned 1.77% of Audentes Therapeutics worth $26,141,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. TD Asset Management Inc. raised its position in shares of Audentes Therapeutics by 19.3% in the second quarter. TD Asset Management Inc. now owns 59,222 shares of the biotechnology company’s stock valued at $2,263,000 after purchasing an additional 9,600 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Audentes Therapeutics in the second quarter valued at about $232,000. Wells Fargo & Company MN raised its position in shares of Audentes Therapeutics by 29.5% in the second quarter. Wells Fargo & Company MN now owns 398,155 shares of the biotechnology company’s stock valued at $15,213,000 after purchasing an additional 90,618 shares during the period. Victory Capital Management Inc. raised its position in shares of Audentes Therapeutics by 35.1% in the second quarter. Victory Capital Management Inc. now owns 739,241 shares of the biotechnology company’s stock valued at $28,246,000 after purchasing an additional 191,950 shares during the period. Finally, Jennison Associates LLC raised its position in shares of Audentes Therapeutics by 1.8% in the second quarter. Jennison Associates LLC now owns 1,020,556 shares of the biotechnology company’s stock valued at $38,995,000 after purchasing an additional 17,877 shares during the period. 88.59% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have recently weighed in on BOLD. HC Wainwright set a $33.00 price objective on shares of Audentes Therapeutics and gave the company a “buy” rating in a research report on Sunday, October 14th. William Blair lowered shares of Audentes Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 6th. Wedbush reissued an “outperform” rating and issued a $49.00 price objective on shares of Audentes Therapeutics in a research report on Wednesday, August 8th. ValuEngine lowered shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, October 12th. Finally, Mizuho raised shares of Audentes Therapeutics from a “neutral” rating to a “buy” rating and set a $26.00 price objective on the stock in a research report on Wednesday, August 8th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $35.49.

BOLD stock opened at $24.45 on Monday. Audentes Therapeutics Inc has a 52 week low of $19.62 and a 52 week high of $46.18. The stock has a market capitalization of $1.04 billion, a P/E ratio of -7.19 and a beta of 1.99.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.97) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.09). During the same quarter last year, the business posted ($0.88) EPS. Research analysts anticipate that Audentes Therapeutics Inc will post -3.38 EPS for the current fiscal year.

In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 12,952 shares of the stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $40.00, for a total transaction of $518,080.00. Following the sale, the chief executive officer now directly owns 12,952 shares in the company, valued at $518,080. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Louis G. Lange sold 24,000 shares of the stock in a transaction dated Thursday, November 15th. The stock was sold at an average price of $22.49, for a total transaction of $539,760.00. Following the sale, the director now owns 345,799 shares in the company, valued at $7,777,019.51. The disclosure for this sale can be found here. Insiders sold 101,039 shares of company stock worth $3,465,020 over the last 90 days. 6.60% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2018/12/03/alliancebernstein-l-p-increases-stake-in-audentes-therapeutics-inc-bold.html.

Audentes Therapeutics Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Read More: Understanding Market Liquidity

Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics Inc (NASDAQ:BOLD).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit